Göran Arvidson new President and CEO of Hansa Medical
Hansa Medical’s acting CEO and CFO Göran Arvidson has been appointed President and CEO of the company, effective from April 30, 2015.
Göran Arvidson joined Hansa Medical as CFO on January 27, 2015. On March 2, he was appointed acting CEO of the company.
"Göran Arvidson has significant experience from the life science sector, which will be of great value for the company going forward. For instance, as one of the founders of Biovitrum, he was instrumental in building one of the most successful Swedish biopharmaceutical companies in recent times”, commented Birgit Stattin Norinder, Chairman of Hansa Medical's board.
Göran's previous positions include Executive Vice President and CFO of Swedish Orphan Biovitrum AB (publ), Co-founder and CFO of Biovitrum, as well as several senior positions in corporate development and finance with Pharmacia AB and Procordia AB. He has a MBA from Stockholm School of Economics. Göran Arvidson owns 3,000 shares in Hansa Medical.
He succeeds Fredrik Lindgren, who leaves the company for personal reasons.
“I want to take the opportunity to thank Fredrik Lindgren for the hard work he put in during a very intensive period of the company. He was, among other things, influential in the process where we managed to secure our financial position, in order to continue our important clinical projects”, said Birgit Stattin Norinder.
The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on April 9, 2015 at 08.00 CET.
For further information, please contact:
Birgit Stattin Norinder, Chairman of the board
Mobile: +46 706 62 61 80
E-mail: birgitsn@telia.com
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.
Tags: